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Abstract
Background: Acne vulgaris, a common skin disease, affects up to 80 % of the population. Moderate to severe
acne requires treatment with a combination of topical and oral drugs such as antibiotics, hormones and retinoids.
Retinoids have many contraindications and adverse effects requiring close monitoring. The study’s objectives were
to describe prescribing trends in acne medication over time in a military setting, and assess physician adherence to
guidelines for acne treatment, including drug precautions, clinical monitoring, and treatment progression.
Methods: We conducted a descriptive, serial cross-sectional study of acne drugs prescribed in the Israel Defense
Forces (IDF) in the years 2002–2007, analyzing the classes of drugs prescribed and patient characteristics. In addition,
the clinical quality of the medical encounter was assessed by examining physician adherence to IDF guidelines.
Results: Between 2002 and 2007, 64,281 patients were treated for acne. Treatment courses generally persisted for 1–2
months. Over 70 % of female patients receiving oral retinoids were not concomitantly receiving oral contraceptives.
Conclusion: This study provides a unique perspective of acne treatment in a military setting, overall displaying good
adherence to general guidelines. The common prescription of oral retinoids to young females without concomitant
contraception is alarming.
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Background
Acne vulgaris is a common inflammatory skin disease with
a complex and multifactorial pathogenesis. Increased
sebum secretion leads to seborrhea and comedogenesis,
while bacterial infection of the comedo, usually by
Propionibacterium acnes, causes inflammation leading to
papules, pustules and nodules [1–3]. Acne commonly
appears on the face, but may also be found on the upper
chest, shoulders and back [2]. It can result in severe
cosmetic blemishing and can be emotionally distressing to
affected individuals, especially to adolescents and young
adults [4].
Acne vulgaris affects over 80 % of the population at
some stage in life, especially young adults. Despite the
high disease prevalence, only about 20–30 % of patients
seek medical treatment [1, 5–7]. Gender distribution is
roughly equal [1, 8, 9] although during adolescence males
are more affected than females [8, 10]. Acne can last sev-
eral years and normally resolves by the mid-twenties. In
recent years, a gradual increase in the age of onset has
been observed and in over 8 % of patients the onset is
after the age of 25, more commonly in women [11].
In the treatment of mild acne, proper hygiene with anti-
septic non-abrasive soap is recommended, as well as a
well-balanced diet [2]. If the problem fails to resolve
spontaneously, topical treatment is usually recommended,
including antibiotics such as clindamycin, erythromycin
and tetracycline, retinoids including tretinoin, isotretinoin
and the tretinoin-like drug adapalene, salicylic acid, azelaic
acid and benzoyl peroxide as mono or combination ther-
apy [1]. In recent years, antibiotic-resistant bacterial
* Correspondence: pharmerster@gmail.com
1Israel Defense Forces Medical Corps, IDF, P.O. Box 02149, Te Hashomer,
Israel
Full list of author information is available at the end of the article
© 2015 Fleischmann et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fleischmann et al. Military Medical Research  (2015) 2:37 
DOI 10.1186/s40779-015-0063-0
strains seem to be developing, and acne is somewhat less
responsive to topical anti-bacterial treatment with erythro-
mycin [12].
Oral contraceptive (OC) treatment may also be con-
sidered as a treatment option for mild acne in women.
In young women, acne is responsive to OC treatment
because it reduces the androgenic effects on increased
sebum secretion [13, 14].
In moderate acne, a second line of treatment is required
with orally administered systemic antibiotics, the most
common of which is minocyclin, with other tetracyclines
such as doxycycline, tetracycline and oxytetracycline in
clinical use [1, 15]. Oral contraceptives are effective in
women with moderate acne, and all oral therapies may be
combined with topical agents for increased effect.
In severe acne, the third and definitive line of treat-
ment is oral isotretinoin (OI) which is a synthetic
form of vitamin A. It significantly reduces size and
sebum production of the sebaceous glands, normal-
izes follicular keratinization and prevents the develop-
ment of micro-comedones and comedones, indirectly
inhibits P. acnes growth by changing the follicular
milieu, and exerts direct anti-inflammatory activity.
Results of OI treatment may be apparent only after a
few weeks, but a full course of treatment can take up
to 6 months. OI is contraindicated in pregnancy be-
cause it is highly teratogenic, and ruling out preg-
nancy is required before commencement of therapy
in females [16]. OIs are associated with several side
effects which require close laboratory and clinical
monitoring [2, 5–7, 17, 18].
Acne in the military setting
Military service is mandatory in Israel, and the young
adults that serve in the Israel Defense Forces (IDF) rep-
resent the majority of males aged 18–21 and females
aged 18–20. The remainder of the military population is
comprised of career and reserve soldiers aged 21 to 45.
During military service, young adults, who are naturally
predisposed to acne vulgaris, are exposed to high levels
of physical and psychological stress, in an environment
often characterized by poor sanitary conditions.
Military organizations worldwide recognize acne as a
significant healthcare issue affecting the daily lives of
soldiers: Acne was reported as one of the top 5 skin condi-
tions affecting military personnel in the Singapore military
[19]. Between 1996 and 1997 16 % of patients (military
and civilian personnel) treated in an Oslo military clinic
were suffering from skin disease, 10 % of whom were suf-
fering from acne vulgaris [20]. Researchers recommended
the appointment of a dermatologist to the military medical
team. More recently, acne was found to be among the
three most common skin problems (35.6 %) in the Korean
military, along with tinea pedis (15.2 %) and atopic derma-
titis (5.1 %) [21].
In the IDF, acne is treated by general practitioners in
primary care clinics, and by medical specialists, such as
dermatologists, family practitioners and gynecologists,
in secondary care clinics. The clinical guidelines for
acne treatment published by the IDF Medical Corps
call for treatment of mild acne with topical prepara-
tions, and consideration of OC treatment in women.
For moderate acne, combination therapy with oral anti-
biotics and local treatment is recommended. For severe
acne, OI is the drug of choice. Since contraindications
for OI treatment include pregnancy and lactation, be-
fore commencing therapy the prescribing physician
must ensure, through reliable laboratory tests, that the
female patient is not pregnant. The physician is re-
quired to explain to the patient that reliable means of
birth control must be in use for at least one month
prior to treatment, during the entire course of the
treatment, and for one month following cessation of
treatment. The patient is required to sign a statement
acknowledging the drug’s teratogenic nature and agree-
ing to take birth control measures for the duration of
treatment, as well as agreeing to inform the treating
physician in case of pregnancy. This statement is filed
in the patient’s medical record. The concomitant use of
OI and tetracycline or its derivatives is strongly contra-
indicated because of the risk of developing benign
intracranial hypertension (pseudotumor cerebri). Also
contraindicated are psychiatric reports of the patient
having developed depression and/or suicidal tendencies
in the past or present. Prior to commencement of and
periodically throughout treatment, all patients must
undergo baseline blood tests, including complete blood
count, liver functions, blood lipids (cholesterol, HDL,
LDL, triglycerides) and CPK levels, and daily dosages
are adjusted accordingly. Accepted dosage is 0.5–
1.0 mg/(kg•d) in two divided doses, over several
months. The maximum daily dose should not exceed
120 mg.
Medical care in the IDF is provided to soldiers free
of charge. Since no monetary barriers are in place,
patients are likely motivated to seek treatment for
medical conditions that might otherwise be consid-
ered minor or expensive, and we can expect to find
within the IDF a large group of patients under med-
ical treatment for acne. However, access to care may
be limited for certain sub-groups, especially those
serving under remote field conditions, leaving some
lesser complaints untreated.
We conducted a descriptive, serial cross-sectional
study of acne drugs prescribed in the IDF during the
years 2002–2007. Our aim was to analyze the classes of
drugs prescribed and patient characteristics, and to
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assess the clinical quality of the medical encounter by




The study database was constructed by combining re-
cords from two existing computerized databases: the
computerized patient record (CPR), a comprehensive
medical file resource, and the IDF pharmacy management
program. The data were assembled and analyzed using
SAS® software, version 9.2. The study was approved by the
IDF Institutional Review Board in accordance with the
Declaration of Helsinki. The database was de-identified
and all information was analyzed while maintaining pa-
tient anonymity.
Doctor patient encounters between the years 2002
and 2007 were searched for the diagnosis of “acne”
(ICD9 code 706.1X). Since this was the only option
available to the examining physicians to code acne
related encounters, this represents a high specificity
and high sensitivity diagnosis. The IDF pharmacy
management program was queried for all acne medi-
cations as defined in Appendix and cross referenced
with the patient records arising from the CPR data-
base, thus creating a record of acne therapy com-
posed of prescribing and dispensing encounters for
the same patients. For each patient with a diagnosis
of acne, the first date of diagnosis in the CPR system
was searched. For every initial diagnosis date located,
the drug prescribing (CPR data) and dispensing
(pharmacy data) dates were compared with the initial
diagnosis date. Patients were included in the data-
base only if the diagnosis preceded the prescribing
or dispensing of acne medication. In order to avoid
bias of medications prescribed to treat other condi-
tions, we then filtered the results and identified
distinct acne encounters limited solely to 1st, 2nd or
3rd line acne medications. All distinct acne encoun-
ters were filtered according to encounter year and
type.
A treatment course was defined as beginning on
the date of the first acne encounter with a specific
group of acne medication and lasting until 30 days
following the last date of prescribing or dispensing a
medication of the same group. If a medication of the
same group was prescribed or dispensed within
45 days of the previous date of prescription or dis-
pensing of a medication of the same group, it was
considered within the course of treatment.
Individual physicians’ clinical experience with acne
treatment at the time of the encounter was obtained by
counting the number of acne encounters recorded
during the preceding 3 months and categorizing them
into low (0–20 %), medium (20–30 %) and high (≥30 %)
experience. Key IDF clinical guideline recommendations
for the treatment of acne and their operational methods
of assessment in the current study are presented in
Table 1. Adherence to guidelines was evaluated by the
appropriateness of treatment sequence and by the docu-
mented prescription of OC’s to female OI recipients. All
treatments were referred to by the year of their
initiation.
Table 1 Key IDF clinical guideline recommendations for the treatment of acne and their operational methods of assessment
Population IDF guideline recommendation Assessment in study
All acne patients Assign treatment according to acne severity Not assessed in study: could not be evaluated by computerized
query (Disease severity not stated within diagnosis field)
All acne patients Progress gradually between treatment lines Correctness of treatment progression assessed for treatment
courses of distinct acne medications (see Table 4)
Patients treated with oral
retinoids
Rule out psychiatric diagnoses prior to treatment
initiation, and refer to psychiatrist if necessary
Not assessed in study: information not available in computerized
patient records
Patients treated with oral
retinoids
Monitor laboratory test values (liver enzymes,
plasma lipid profile) before and during treatment.
Not assessed in study: computerized laboratory test records were
not available for cross analysis between databases.
Patients treated with oral
retinoids
Prescribe supportive care if necessary. Concomitant prescribing or dispensing of supportive care
medications was assessed (see Table 5).
Patients treated with oral
retinoids
Restrict patient participation in strenuous physical
activity by temporarily adjusting medical profile.
Not assessed in study: documentation of temporary change in
medical profile was not available after reinstatement of
permanent profile.
Female patients treated with
oral retinoids (teratogenic)
- Rule out pregnancy (laboratory test). Documented concomitant prescribing or dispensing of oral
contraceptives to female patients receiving OI’s.
- Inform the patient of potential hazards and
explain about required birth control measures.
- Have the patient sign a statement and file in their
medical record (see background).
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Analysis
All descriptive data of the patients, physicians and en-
counters were stratified by year. Continuous care was
then analyzed in the form of treatment courses. Some
missing information between the years 2002 and 2003,
which we surmised to arise from the incomplete process
of CPR software assimilation, led us to re–define and re-
analyze the continuous elements of the information
which could not be stratified annually, so that only the
years with comprehensive data from all sources were
included in the analysis. The non-stratified analyses
therefore relate to the years 2004–2007. The lack of
grading options in the CPR regarding acne severity pre-
vented a stratified analysis of appropriateness of treat-
ment. Therefore, we analyzed the treatment sequence
according to medication type (1st, 2nd, 3rd line, OC’s,
non-specific acne treatment, supportive care), as shown
in Appendix. We also assessed the logical progression of
treatment, from 1st to 2nd and 3rd lines. The assess-
ment of physician monitoring of OI therapy included
the prescribing of oral contraceptives in female patients
prior to or during therapy, restricting the patients’
participation in strenuous physical activity and prescrib-
ing concomitant supportive care.
Results
Over the study period, we identified 159,316 encounters
with acne recorded as the diagnosis, representing 64,281
individual patients. Collectively, these patients were pre-
scribed acne medications on 225,015 occasions. Comput-
erized pharmacy data were available from 2004, allowing
us to query dispensing encounters from this point on.
During this 4 year period 50,942 patients received acne
medication on 179,540 individual occasions yielding a rate
of 3.52 prescriptions filled per patient. For acne patients,
acne medications represented 41.7 % of all prescriptions
written (Table 2).
Patient characteristics are shown in Table 3. As expected
in a conscript army, the vast majority of patients were
aged 18–21, and nearly two thirds of patients (63.6 %)
were male. Over 90 % of both males and females had a
high school education. Nearly 80 % of patients were born
in Israel, and their ethnic backgrounds were varied.
Trends in patient volume over time are shown in
Table 4. While the number of female patients increased
gradually and remained stable form 2004 to 2007, the
number of male patients peaked in 2005 and decreased
Table 2 Patients, physician visits and prescription volumes, by
study period (n)
Description 2002–2007 2004–2007
CPR encounters with acne diagnosis 159,316 129,672
Number of patients treated for acne 64,281 50,942
Prescribing encounters 225,015 193,313
All drug dispensing encounters N/A 430,851
Acne drug dispensing encounters N/A 179,540
N/A: not available
Table 3 Patient characteristics, by sex
Variable Number % of
total
% male % female
Patients 64,179 100.0 63.6 36.4
Age (year)
≤21 59,928 93.4 91.7 96.3
22–28 3,656 5.7 7.3 2.9
≥29 595 0.9 1.0 0.8
Education
Elementary 63 0.1 0.1 0.0
High school 59,578 92.8 90.5 96.9
Post-high school 4,415 6.9 9.1 2.9
Unknown 123 0.2 0.2 0.2
Ethnicity
Israel 4,853 7.6 8.4 6.1
Asia + Africa + Ethiopia 30,215 47.1 45.2 50.3
West 15,329 23.9 24.6 22.7
Former Soviet Union 8,187 12.8 13.3 11.9
Unknown 5,595 8.7 8.6 9.0
Country of
birth
Israel 50,726 79.0 78.4 80.1
Asia, Africa 1,298 2.0 2.4 1.5
West 1,861 2.9 3.1 2.6
Former Soviet Union 6,776 10.6 10.8 10.1
Unknown 3,518 5.5 5.3 5.8
Table 4 Correctness of treatment sequence
Year of
diagnosis
Patients (n) Treatments (n)
Male Female Total Incorrect Correct Total
2002 4,991 2,551 7,542 293 4,141 4,434
2003 6,651 3,071 9,722 423 6,115 6,538
2004 7,967 4,235 12,202 695 8,223 8,918
2005 8,905 4,451 13,356 677 9,054 9,731
2006 7,560 4,654 12,214 522 8,479 9,001
2007 4,727 4,416 9,143 204 6,274 6,478
Total 64,179 40,801 23,378 2814 42,286 45,100
The following treatment combinations and progressions were considered
correct: 1st line therapy before or in combination with 2nd or 3rd line therapy;
and 2nd before 3rd line therapy. The following were considered incorrect: 2nd
before 1st line and 3rd before or in combination with 2nd line therapy
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through 2007. This pattern in male soldiers likely repre-
sents, at least in part, technical limitations of the data
set in later years.
Slightly more than half of the encounters yielded a pre-
scribed medication (56 %), and most were performed in
primary care facilities (70 %). When prescribed, the treat-
ment of choice was mainly 1st line monotherapy, followed
by 2nd line, 3rd line and OC’s, with other non-distinct acne
medications being the least chosen therapy. Supportive
care was prescribed in 678 encounters (Table 5).
The majority of treating physicians (76 %) had limited
medical expertise, and the majority of encounters were
held in primary care facilities (97 %), suggesting that
most of the acne diagnosis and care in the IDF is
performed in primary care unit clinics by physicians less
experienced with acne treatment. Treatment in second-
ary care facilities was relatively uncommon (2.7 % of all
encounters), but was often given by more experienced
physicians.
Drug prescriptions peaked during 2006 at 28,491
prescriptions. Figure 1 shows trends over time in pre-
scription volume for 1st, 2nd and 3rd lines of ther-
apy. The use of 1st line therapy increased more than
fourfold between 2002 and 2006, peaking at just
under 19,000 prescriptions annually. Between 2002
and 2005, 2nd line drug prescriptions increased three
fold, from 2,400 to 7,400 annually. While absolute
numbers of 3rd line therapies were substantially
lower, they more than doubled in annual volume be-
tween 2004 and 2006.
Therapy courses mostly persisted for no longer than 1–
2 months. As expected, the majority of long-term treat-
ments (spanning several months) were those of 3rd line
therapies, however, most patients did not continue to take
the full course of therapy (4–6 months) as commonly rec-
ommended. 4,234 correct treatment courses displayed
progress from 1st to 2nd line therapy, representing 10 %
of correct treatment courses, and 38 % of correct 2nd line
combination therapy courses. 1,465 correct treatment
courses displayed progress from 2nd to 3rd line therapy,
representing 3.5 % of correct treatment courses, and
51.5 % of correct 3rd line combination therapy courses.
Incorrect progression between drug lines represented less
than 7 % of all treatments.
We examined all OI treatment courses in female
patients for concomitant oral contraceptives, includ-
ing treatment initiated 30 days before treatment
commencement.
An alarming finding was that more than 70 % of female
patients prescribed 3rd line therapy did not receive oral
contraceptives during the course of the acne treatment or
temporally adjacent to it.
Discussion
Acne is a highly prevalent medical condition in the military
population. Although not life-threatening, it does have
some severe social and psychological ramifications. There
may be additional operational impact, since the side effects
of some acne medications include increased photosensitiv-
ity and additional symptoms which may be exacerbated
among soldiers training and operating in heightened phys-
ical and mental stress and under extreme environmental
conditions.
In this community setting of adolescents and young
adults in the military, the majority of acne related patient-
physician encounters ended with a prescribed medication.
Most treatment courses were short, and most patients
taking 3rd line medications failed to complete the full
course of treatment. Incorrect progression between drug
lines was rare.
The vast majority of female patients prescribed 3rd
line therapy did not receive concomitant oral
contraceptives.
The availability of computerized data on both clin-
ical encounters and pharmacy dispensing provided a
unique opportunity to describe the characteristics of
acne treatment in a population of adolescents and
young adults. The majority of the study population
was male, which is not surprising in a military envir-
onment 44 % of patient encounters did not end in
any drug prescription. It should be noted, however,
that these data do not represent individual patients,
but rather the encounters these patients underwent.
It is possible that some of these encounters represent
follow-up sessions performed by treating physicians,
after having provided the patient with multiple pre-
scriptions on a previous encounter. Another explan-
ation could be referral of patients by unit physicians
to secondary care facilities. This information can be
of use as a benchmark by medical organizations pro-
viding volume of patient encounters. Trends in medi-
cation prescription increased over the study period,
while the patient population remained stable. This
may indicate increased patient awareness and demand
for medications, increased physician prescribing habits
Table 5 Acne treatments by type, 2004–2007
Treatment Number Mono therapy Combination
therapy
1st line (topical) 54,999 43,325 11,674
2nd line (oral antibiotics) 26,645 15,878 10,767
3rd line (oral retinoid) 11,602 10,815 787
Oral contraceptives 3,347 3,003 344
Non-distinct acne medication 892 330 562
Supportive care 678 53 625
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or both. Our data indicate that the vast majority of
acne diagnosis and care in the IDF is performed in
primary care clinics by physicians less experienced
with acne treatment. This observation underscores
the importance of having clear and precise clinical
guidelines in place to ensure a uniform standard of
treatment. More than half of 3rd line treatment
courses ended after 2 to 3 months, whereas treatment
guidelines call for 4–6 months of continuous therapy
in order to achieve maximal benefit in most patients.
This finding may represent insufficient therapy due to
poor patient compliance among soldiers in the mili-
tary setting, or less than optimal treatment practices
by physicians. However, this may in some measure
indicate the high patient turnover in the military
environment due to cyclic recruitment and discharge
cycles of conscripted military personnel. Limited
accessibility of medical treatment may also be a con-
tributing factor. There may also be additional expla-
nations for this finding such as disrupted treatment
courses among soldiers serving far away from medical
facilities where the medication could be dispensed, or
low treatment compliance due to side effects.
The assessment of treatment progression demon-
strated that the vast majority of treatments were chrono-
logically correct. This finding is encouraging. However,
it is noteworthy that at the time of this study, it was not
possible to define the severity of the diagnosis, so that
we were unable to examine the allocation of treatment
according to the grade of acne.
The finding that oral contraceptives were infre-
quently used by female patients taking OI’s is con-
cerning. It is possible that some female patients were,
in fact, taking OC’s purchased outside of the military.
Alternatively, this finding may represent a high rate
of sexual abstinence in our study population.
However, the possibility of sexual activity and unin-
tentional pregnancy together with the teratogenic po-
tential of OI should encourage physicians to
prescribe, and patients to take, oral contraceptives
during OI treatment. This issue should be stressed
among prescribing physicians. It is also possible that
treating physicians found the signing of a statement
by the patient to be sufficient, since prescribing oral
contraceptives was not an absolute prerequisite to OI
treatment in female patients, especially when they
claim to not be sexually active.
Conclusion
The purpose of this study was to describe acne treat-
ment in the IDF in the years 2002–2007. This study pro-
vides a unique perspective of acne treatment in a
military setting, overall displaying good adherence to
general guidelines. The common prescription of oral ret-
inoids to young females without concomitant contracep-
tion is alarming.
Limitations of this study
The data analyzed in this study were collected from the
CPR, which was widely in use by 2002, and provided full
coverage by 2004. While it is possible that some of the
increase in trend was artifactual due to the increase in
CPR coverage, this contribution was likely minor and
certainly could not account for the continuing rise ob-
served from 2004 and onwards.
Fig. 1 Trends in acne prescriptions over time, by line of therapy
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